

# Kwan Yeung Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5197619/publications.pdf>

Version: 2024-02-01

27  
papers

1,146  
citations

393982

19  
h-index

525886

27  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1698  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic inactivation of the miR-34a in hematological malignancies. <i>Carcinogenesis</i> , 2010, 31, 745-750.	1.3	160
2	Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies. <i>PLoS ONE</i> , 2011, 6, e19027.	1.1	153
3	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2760-2767.	1.6	89
4	DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. <i>Epigenomics</i> , 2011, 3, 83-92.	1.0	69
5	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NF $\kappa$ B pathway. <i>Molecular Cancer</i> , 2013, 12, 173.	7.9	66
6	Epigenetic inactivation of the MIR34B/C in multiple myeloma. <i>Blood</i> , 2011, 118, 5901-5904.	0.6	63
7	Epigenetic silencing of MIR203 in multiple myeloma. <i>British Journal of Haematology</i> , 2011, 154, 569-578.	1.2	63
8	DNA methylation of microRNA genes in multiple myeloma. <i>Carcinogenesis</i> , 2012, 33, 1629-1638.	1.3	62
9	Epigenetic inactivation of the MIR129-2 in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2013, 6, 16.	6.9	59
10	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. <i>Molecular Cancer</i> , 2015, 14, 175.	7.9	40
11	Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. <i>Journal of Translational Medicine</i> , 2011, 9, 197.	1.8	38
12	Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2. <i>British Journal of Cancer</i> , 2008, 99, 283-293.	2.9	33
13	Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. <i>Oncotarget</i> , 2014, 5, 9770-9782.	0.8	30
14	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. <i>Epigenomics</i> , 2015, 7, 985-1001.	1.0	29
15	Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 82400-82410.	0.8	26
16	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. <i>Clinical Epigenetics</i> , 2019, 11, 71.	1.8	23
17	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. <i>Oncotarget</i> , 2015, 6, 44422-44436.	0.8	21
18	Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2015, 68, 557-561.	1.0	20

#	ARTICLE	IF	CITATIONS
19	High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. <i>Journal of Hematology and Oncology</i> , 2016, 9, 107.	6.9	20
20	Epigenetic silencing of LPP/miR-28 in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2018, 71, 253-258.	1.0	15
21	DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin's Lymphomas. <i>Frontiers in Genetics</i> , 2012, 3, 233.	1.1	14
22	Epigenetic silencing of EVL/miR-342 in multiple myeloma. <i>Translational Research</i> , 2018, 192, 46-53.	2.2	14
23	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 728-737.	1.2	14
24	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. <i>Cancer Cell International</i> , 2013, 13, 122.	1.8	11
25	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 13522.	1.6	11
26	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 7009.	1.6	2
27	Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation. <i>Bone Marrow Transplantation</i> , 2014, 49, 1545-1547.	1.3	1